 Christopher Striebich
Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 13 | 2023 | 1104 | 1.060 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.370 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 78 | 0.350 |
Why?
| | Antirheumatic Agents | 2 | 2023 | 279 | 0.280 |
Why?
| | Interferon-alpha | 2 | 2021 | 192 | 0.280 |
Why?
| | Rheumatoid Factor | 4 | 2022 | 168 | 0.270 |
Why?
| | Autoantibodies | 6 | 2023 | 1463 | 0.250 |
Why?
| | Endothelium, Vascular | 1 | 2011 | 847 | 0.230 |
Why?
| | Meniscus | 1 | 2023 | 22 | 0.210 |
Why?
| | Rheumatology | 1 | 2023 | 106 | 0.200 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 423 | 0.190 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2023 | 140 | 0.180 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2002 | 334 | 0.180 |
Why?
| | STAT1 Transcription Factor | 1 | 2021 | 70 | 0.180 |
Why?
| | Lovastatin | 1 | 2020 | 27 | 0.170 |
Why?
| | Anti-Citrullinated Protein Antibodies | 2 | 2020 | 111 | 0.170 |
Why?
| | Osteoarthritis, Knee | 1 | 2023 | 239 | 0.170 |
Why?
| | Methotrexate | 2 | 2021 | 248 | 0.170 |
Why?
| | STAT3 Transcription Factor | 1 | 2021 | 190 | 0.160 |
Why?
| | Interleukin-10 | 1 | 2021 | 299 | 0.150 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2023 | 300 | 0.150 |
Why?
| | Synovial Fluid | 1 | 1998 | 66 | 0.150 |
Why?
| | Rheumatic Diseases | 1 | 2019 | 69 | 0.150 |
Why?
| | C-Reactive Protein | 1 | 2020 | 397 | 0.140 |
Why?
| | B-Lymphocytes | 3 | 2012 | 817 | 0.140 |
Why?
| | Triage | 1 | 2019 | 206 | 0.140 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2017 | 137 | 0.130 |
Why?
| | Autoimmunity | 2 | 2012 | 860 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 413 | 0.130 |
Why?
| | Interferon-beta | 1 | 2015 | 87 | 0.120 |
Why?
| | Epitopes | 3 | 2023 | 466 | 0.120 |
Why?
| | Wrist Injuries | 1 | 2014 | 27 | 0.110 |
Why?
| | Ligaments, Articular | 1 | 2014 | 59 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 87 | 0.110 |
Why?
| | Rituximab | 2 | 2011 | 162 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2020 | 1060 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1998 | 1046 | 0.100 |
Why?
| | Range of Motion, Articular | 1 | 2014 | 386 | 0.100 |
Why?
| | Bronchial Diseases | 1 | 2011 | 38 | 0.100 |
Why?
| | Muscle Strength | 1 | 2014 | 305 | 0.090 |
Why?
| | Labor, Induced | 1 | 2011 | 30 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2015 | 1185 | 0.090 |
Why?
| | Cyclophosphamide | 1 | 2011 | 227 | 0.090 |
Why?
| | Recovery of Function | 1 | 2014 | 641 | 0.090 |
Why?
| | Genes, Immunoglobulin | 1 | 1990 | 28 | 0.090 |
Why?
| | Immune Tolerance | 1 | 2012 | 349 | 0.080 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 130 | 0.080 |
Why?
| | Health Fairs | 1 | 2009 | 9 | 0.080 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 1990 | 80 | 0.080 |
Why?
| | Synovitis | 1 | 2009 | 25 | 0.080 |
Why?
| | Signal Transduction | 2 | 2021 | 4826 | 0.080 |
Why?
| | Humans | 19 | 2023 | 128418 | 0.080 |
Why?
| | Treatment Outcome | 5 | 2020 | 10152 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1009 | 0.070 |
Why?
| | Middle Aged | 10 | 2021 | 30889 | 0.070 |
Why?
| | Aspirin | 1 | 2011 | 376 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 518 | 0.070 |
Why?
| | Female | 13 | 2022 | 68154 | 0.070 |
Why?
| | Immunoglobulin M | 2 | 2022 | 272 | 0.070 |
Why?
| | Adult | 8 | 2021 | 35300 | 0.070 |
Why?
| | Biomarkers | 4 | 2021 | 3880 | 0.060 |
Why?
| | Lung Diseases | 1 | 2011 | 715 | 0.060 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2008 | 245 | 0.060 |
Why?
| | Male | 12 | 2022 | 62858 | 0.060 |
Why?
| | Rheumatologists | 1 | 2023 | 15 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 680 | 0.050 |
Why?
| | Phosphorylation | 2 | 2021 | 1681 | 0.050 |
Why?
| | Risk Factors | 3 | 2023 | 9704 | 0.050 |
Why?
| | Peptides, Cyclic | 2 | 2017 | 255 | 0.050 |
Why?
| | Incidence | 2 | 2020 | 2616 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 34 | 0.050 |
Why?
| | Complementarity Determining Regions | 1 | 2002 | 49 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2021 | 2722 | 0.050 |
Why?
| | Colorado | 3 | 2020 | 4375 | 0.050 |
Why?
| | Clone Cells | 2 | 2002 | 255 | 0.050 |
Why?
| | Prospective Studies | 3 | 2022 | 7036 | 0.050 |
Why?
| | Mass Screening | 1 | 2009 | 1147 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 2 | 2021 | 539 | 0.050 |
Why?
| | Aged | 5 | 2021 | 21953 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1355 | 0.050 |
Why?
| | Abatacept | 1 | 2021 | 47 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 201 | 0.040 |
Why?
| | Complement Activation | 1 | 2023 | 365 | 0.040 |
Why?
| | Joints | 2 | 2011 | 95 | 0.040 |
Why?
| | Sequence Analysis | 1 | 1998 | 37 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2002 | 2040 | 0.040 |
Why?
| | Pregnancy | 1 | 2011 | 6357 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2002 | 1098 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 2002 | 2819 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2021 | 7033 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2002 | 846 | 0.030 |
Why?
| | HIV-1 | 1 | 2002 | 836 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2020 | 1848 | 0.030 |
Why?
| | Patient Selection | 1 | 2019 | 663 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1023 | 0.030 |
Why?
| | Base Sequence | 1 | 1998 | 2135 | 0.030 |
Why?
| | Lunate Bone | 1 | 2014 | 9 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1263 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1196 | 0.030 |
Why?
| | Scaphoid Bone | 1 | 2014 | 19 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2710 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3328 | 0.030 |
Why?
| | Syk Kinase | 1 | 2012 | 21 | 0.030 |
Why?
| | Immunoglobulin D | 1 | 2012 | 29 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2012 | 21 | 0.030 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2012 | 28 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5039 | 0.030 |
Why?
| | Clonal Anergy | 1 | 2012 | 51 | 0.030 |
Why?
| | Young Adult | 3 | 2015 | 12312 | 0.020 |
Why?
| | Arthrography | 1 | 2011 | 17 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2012 | 126 | 0.020 |
Why?
| | Antigens, CD19 | 1 | 2012 | 115 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2022 | 14454 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3232 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1815 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1998 | 1900 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1935 | 0.020 |
Why?
| | Databases, Factual | 1 | 2015 | 1269 | 0.020 |
Why?
| | Blotting, Northern | 1 | 1990 | 198 | 0.020 |
Why?
| | Immunoglobulin Variable Region | 1 | 1990 | 79 | 0.020 |
Why?
| | Cross Reactions | 1 | 1990 | 128 | 0.020 |
Why?
| | Hybridomas | 1 | 1990 | 234 | 0.020 |
Why?
| | Antibody Specificity | 1 | 1990 | 182 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 391 | 0.020 |
Why?
| | Autoantigens | 1 | 2012 | 416 | 0.020 |
Why?
| | Molecular Weight | 1 | 1990 | 331 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 1990 | 292 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 431 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2009 | 155 | 0.020 |
Why?
| | Multigene Family | 1 | 1990 | 198 | 0.020 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 96 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2012 | 430 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 1990 | 530 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 234 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4892 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 27 | 0.020 |
Why?
| | Registries | 1 | 2015 | 1877 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 150 | 0.020 |
Why?
| | HIV Infections | 1 | 2002 | 2701 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2008 | 129 | 0.020 |
Why?
| | Prognosis | 1 | 2015 | 3772 | 0.020 |
Why?
| | United States | 1 | 2022 | 13830 | 0.010 |
Why?
| | Gene Expression | 1 | 1990 | 1456 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2523 | 0.010 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2002 | 21 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3020 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2002 | 218 | 0.010 |
Why?
| | Inflammation | 1 | 2011 | 2654 | 0.010 |
Why?
| | Adolescent | 2 | 2014 | 20179 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2002 | 409 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 771 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2002 | 1142 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 5362 | 0.010 |
Why?
| | Mice | 1 | 1990 | 16602 | 0.010 |
Why?
| | Infant | 1 | 2002 | 8914 | 0.000 |
Why?
| | Animals | 1 | 1990 | 34479 | 0.000 |
Why?
| | Child, Preschool | 1 | 2002 | 10384 | 0.000 |
Why?
| | Child | 1 | 2002 | 20655 | 0.000 |
Why?
|
|
Striebich's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|